Top
image credit: Rawpixel

FDA Panel Skeptical of Controversial ALS Drug Ahead of Vote

September 6, 2022

Via: Drugs.com
Category:

U.S. Food and Drug Administration panel will once again consider approval for an experimental drug for ALS, a rare second review for a disease that has no cure.

The same panel that will meet Wednesday voted last March not to approve the drug for the deadly neurodegenerative condition that’s also known as Lou Gehrig’s disease.

But getting the drug, known as Albrioza (AMX0035), approved is a rallying cause for patients, their families and members of Congress, the Associated Press reported.

Read More on Drugs.com